1. Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial 
Douglas L. Mann, MD, Spencer H. Kubo, MD, Hani N. Sabbah, PhD, Randall C. Starling, MD, Mariell Jessup, MD, Jae K. Oh, MD, Michael A. Acker, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 143, Issue 5, Pages (May 2012)
DOI: /j.jtcvs
Copyright © Terms and Conditions

2. Figure 1
Kaplan-Meier mortality curve for the no-MVR stratum over 5 years of follow-up. Patients in the treatment group (T) are in the solid line and patients in the control group (C) are in the dotted line. The mortality curves between the treatment and control groups were similar, demonstrating the lack of any late adverse effect on mortality. CSD, Cardiac support device.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © Terms and Conditions

3. Figure 2
Longitudinal regression analysis for changes in left ventricular (LV) end-diastolic volume in the no-MVR stratum. The control group did not demonstrate any consistent changes in LV end-diastolic volume over 5 years. In contrast, the CSD treatment group showed a progressive decrease in LV end-diastolic volume that was persistent over 5 years. When averaged over 5 years, the LV end-diastolic volume of the treatment group was smaller by 28.9 mL than that of the control group (P = .029).
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © Terms and Conditions

4. Figure 3
Longitudinal regression analysis for changes in left ventricular sphericity index in the no-MVR stratum. The treatment group had a much larger increase in sphericity index, indicating a change to a more ellipsoidal shape. The average 5-year treatment–control difference was units, which was not statistically significant.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © Terms and Conditions

5. Figure 4
Longitudinal regression analysis for the percentage of patients with an improvement in New York Heart Association (NYHA) functional class of 1 class or more over 5 years of follow-up in the no-MVR stratum. At each time point, there were more patients in the treatment group who improved by at least 1 NYHA functional class. When averaged over 5 years, this difference was highly significant. Trt, Treatment; Ct, control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © Terms and Conditions

6. Figure 5
Kaplan-Meier estimate for the composite of death and major cardiac procedure for the focused cohort of the no-MVR stratum. There was a large separation between the groups that was maintained through 5 years of follow-up. The treatment group had fewer deaths, heart transplants, left ventricular assist devices, and biventricular pacemakers. CSD, Cardiac support device; T, treatment; C, control.
The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs )
Copyright © Terms and Conditions